Open an account

Niagen Bioscience

NAGE · NASDAQ

$2.51+$0.01 (+0.40%)TodayMarket closed ·
Prev close $2.50

About NAGE

Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. The company is headquartered in Los Angeles, California and currently employs 117 full-time employees. The company went IPO on 2007-06-25. Its segments include Consumer Products, Ingredients segment, Analytical Reference Standards and Services and Pharmaceuticals. The Consumer Products segment provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors. The ingredients segment develops and commercializes proprietary-based ingredient technologies, including food-grade Niagen and pharmaceutical-grade Niagen, and supplies these ingredients as raw materials to the manufacturers of consumer products and outsourcing facilities. The Analytical Reference Standards and Services segment offer the supply of phytochemical reference standards and other research and development services. The Pharmaceutical segment focuses on the pharmaceutical development of its nicotinamide adenine dinucleotide (NAD) precursor portfolio for potential therapeutic applications in rare diseases.

Employees
117
Headquarters
Los Angeles, California
Listed
Jun 25, 2007
Sector
Consumer Staples
Industry
Personal Care Products
Website
niagenbioscience.com

NAGE key statistics

Market cap
198.61M
Price-earnings ratio
13.89
Dividend yield
—
Average volume
566.69K
Volume
518.63K
Open price
$2.50
High today
$2.54
Low today
$2.48
52 Week high
$7.95
52 Week low
$2.44

Niagen Bioscience (NAGE) at a glance

Niagen Bioscience (NAGE) last traded at $2.51, with a market cap of 198.61M and a price-to-earnings ratio of 13.89.

Today the stock has traded between $2.48 and $2.54. The current price is 1.2% above the day's low and 1.0% below its high.

Volume so far is 518.63K shares, in line with the average of 566.69K shares a day.

Over the past year Niagen Bioscience has ranged from $2.44 to $7.95, and now sits 1% of the way up that range.

Niagen Bioscience met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q2 FY26 it reported $0.01 per share against an estimate of $0.0153.

The average analyst price target is $12.32, 391.0% above the current price, from 2 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 2 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 8 analystsAvg $12.32
Low
$8.59
Now
$2.51
High
$23.10

NAGE earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 214.8% on average.

  1. Q3 FY24: reported $0.02 per share against an estimate of $0.0034
  2. Q4 FY24: reported $0.09 per share against an estimate of $0.0204
  3. Q1 FY25: reported $0.06 per share against an estimate of $0.017
  4. Q2 FY25: reported $0.04 per share against an estimate of $0.0143
  5. Q3 FY25: reported $0.05 per share against an estimate of $0.0163
  6. Q4 FY25: reported $0.03 per share against an estimate of $0.0224
  7. Q1 FY26: reported $0.07 per share against an estimate of $0.0694
  8. Q2 FY26: reported $0.01 per share against an estimate of $0.0153

NAGE news

  • Press releaseBusiness Wire

    Niagen Bioscience Makes Skincare a Permanent Tru Niagen® Category, Launching Dermatologist-Tested Niagen NanoCloud™ as a Core Tru Niagen® Product

  • Press releaseBusiness Wire

    Niagen Bioscience to Report Third Quarter 2026 Financial Results on Wednesday, November 4, 2026

  • Press releaseBusiness Wire

    Andrew Shao, Ph.D., Senior Vice President of Global Regulatory and Scientific Affairs at Niagen Bioscience, Honored with the 2026 Annette Dickinson Trailblazer Award by Radicle Science and Council for Responsible Nutrition (CRN)

  • Press releaseBusiness Wire

    Niagen Bioscience to Present at LD Micro 20th Annual Main Event

  • Press releaseBusiness Wire

    Niagen Bioscience Puts 25 Years of NAD+ Science Behind "Don't Get Old. Age Better.®” a New Campaign for its Niagen® Brand Featuring Legendary Surfer Kelly Slater

  • Press releaseBusiness Wire

    Niagen Bioscience Announces Start-Up Agreement With Mass General Brigham (MGB) Investigators For First-Of-Its-Kind Healthy Aging Clinical Trial

  • Press releaseBusiness Wire

    Newly Published Preclinical Study Demonstrates CD38 as a Driver of Age-Related NAD+ Decline, Older Mothers Have Lower NAD+ Levels in Placental Tissue, and NAD+ Restoration with Nicotinamide Riboside (NR) Improves Pregnancy Outcomes

  • Press releaseBusiness Wire

    Niagen Bioscience Engages Veteran Pharmaceutical Executives and Biotechnology Experts to Support Drug Development Program and Strategic Business Growth

Similar companies

Companies in the same industry as Niagen Bioscience

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.